Clinical trials: Hematological Neoplasm
Hematopoietic Neoplasms (Leukemia, Lymphoma, Multiple Myeloma)
In Person and Mobile Health Coping Skills Training for Improving Symptom Management and Daily Steps in Hematopoietic Stem Cell Transplant Patients
The purpose of the study is to assess the feasibility, acceptability, and efficacy of a novel mHealth behavioral intervention to enable HCT patients to effectively cope with symptoms to improve their ability to engage in physical…
- Trial name
- CST Step Up (NCT03960619)
- Testing
- coping skills training
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Duke University
Essential Thrombocythemia, Polycythemia Vera
Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis
This phase I trial studies the side effects and best dose of arsenic trioxide with or without ascorbic acid in treating patients with myelofibrosis.
- Conditions
- Essential Thrombocythemia, Polycythemia Vera, Primary Myelofibrosis
- Trial name
- NCT01014546
- Testing
- Arsenic Trioxide, Ascorbic Acid, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Roswell Park Cancer Institute
Advanced Malignancies, Solid Tumor
Study Evaluating Food Effect and QTc in Patients With Advanced Malignancies
Phase 1 2-part study to evaluate the effect of food on pharmacokinetics of pelabresib (CPI-0610) and the effect of pelabresib on QTc in patients with advanced malignancies
- Conditions
- Advanced Malignancies, Solid Tumor, Hematological Malignancy
- Trial name
- NCT05391022
- Testing
- Pelabresib
- Where
- 10 sites in United States, Georgia and 1 more
- Volunteers
- 35 people
- Sponsor
- Constellation Pharmaceuticals
Cancer
Influenza Vaccination in Cancer Patients
The purpose of this study is to determine the timing of influenza vaccination to induce higher antibody response in adult patients with non-hematologic malignancies receiving scheduled cytotoxic chemotherapy.
- Trial name
- NCT02213432
- Testing
- Different timing of influenza vaccination
- Where
- South Korea
- Volunteers
- 97 people
- Sponsor
- Seoul National University Hospital
Multiple Myeloma (MM), Hematologic Neoplasm
Factors Associated With Health-related Quality of Life and Social Participation of Patients With Multiple Myeloma and Their Caregivers
Individuals with multiple myeloma (MM) are vulnerable because of the effects of systemic organ damage and the side effects of treatment.
- Trial name
- MMYLIFE (NCT07014865)
- Where
- Italy
- Volunteers
- 190 people
- Sponsor
- Azienda USL Reggio Emilia - IRCCS
Leukemia, Lymphoma
Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders
RATIONALE: Giving chemotherapy drugs, such as fludarabine and melphalan, before a donor bone marrow transplant or peripheral blood stem cell transplant helps stop the patient's immune system from rejecting the donor's stem cells…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00008307
- Testing
- anti-thymocyte globulin, cyclosporine, fludarabine phosphate
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Herbert Irving Comprehensive Cancer Center
Hematological Malignancy
A New Dosing Regimen for Posaconazole Prophylaxis in Children Based on Body Surface Area
A new prophylactic posaconazole dosing regimen of 120mg/m² tid is evaluated pharmacologically in children 13 years and younger, suffering from a hematologic malignancy.
- Trial name
- NCT02372357
- Testing
- Posaconazole prophylaxis 120 mg/m² tid, Blood sampling
- Where
- 2 sites in Belgium, Romania
- Volunteers
- 14 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Relapsed/Refractory Hematological Malignancies
A Study of TQB3473 Tablets in Subjects With Relapsed or Refractory Hematological Malignancies
This is a study to evaluate the maximum tolerated dose (MTD), occurrence of all adverse events (AE) and serious adverse events (SAE) , pharmacokinetic parameters and antitumor effect of TQB3473 tablets in Chinese adult patients…
- Trial name
- NCT04412577
- Testing
- TQB3473
- Where
- 2 sites in China
- Volunteers
- 57 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Fungal Infection
Fungal Infections in Patients With Hematological Malignancies
Report the prevalence of fungal infections among patients with hematological malignancies in South Egypt Cancer Institute. * Detect the most endemic fungal pathogen isolated from patients with hematological malignancies in South…
- Trial name
- NCT03650439
- Testing
- culture on Sabouraud's Dextrose Agar (SDA)
- Volunteers
- 50 people
- Sponsor
- Assiut University
Leukemia, Lymphoma
Chemotherapy Plus Radiation Therapy and Biological Therapy in Treating Patients With Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00002553
- Testing
- cyclophosphamide, allogeneic bone marrow transplantation, low-LET cobalt-60 gamma ray therapy
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Fred Hutchinson Cancer Center
Chronic Myeloproliferative Disorders, Leukemia
Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT00104975
- Testing
- alemtuzumab, therapeutic allogeneic lymphocytes, fludarabine phosphate
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Yale University
Tumor Lysis Syndrome
Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies
The purpose of this study is to determine whether febuxostat is superior to allopurinol in the prevention of tumor lysis syndrome (TLS) in patients with hematological malignancies at intermediate or high risk of TLS (according to…
- Trial name
- FLORENCE (NCT01724528)
- Testing
- Febuxostat, Allopurinol
- Volunteers
- 346 people
- Sponsor
- Menarini Group
Multiple Myeloma, Hematological Neoplasms
VALEO: A Post Authorization Study, Designed to Learn More About the Safety and Effectiveness of the Use of Bortezomib in the Netherlands
The main purpose of this study is to evaluate safety and effectiveness of the treatment of multiple myeloma with bortezomib in daily practice in the Netherlands.
- Trial name
- NCT00440765
- Testing
- bortezomib
- Where
- 44 sites in Netherlands
- Volunteers
- 331 people
- Sponsor
- Janssen-Cilag B.V.
Hematologic Malignancies
The Safety and Efficacy of the Regimen of Thiotepa + Fludarabine +Granulocyte Colony-Stimulating Factor+ Cytarabine + Busulfan in Single Unrelated Umbilical Cord Blood Transplantation
This trial is a prospective, single-arm, single-center clinical study. A total of 44 elderly (aged 60 to 69 years) patients with hematological malignancies who need to receive a single-unit unrelated umbilical cord blood…
- Trial name
- NCT07441967
- Testing
- Thiotepa, Fludarabine, G-CSF
- Volunteers
- 44 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Acute Leukemia, Chronic Leukemia
Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant
This is a phase 1, interventional single arm, open label, treatment study designed to evaluate the safety combination programmed cell death protein 1 (PD-1) and interleukin 6 (IL-6) inhibition in participants with relapsed…
- Conditions
- Acute Leukemia, Chronic Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT03588936
- Testing
- Nivolumab (.25 mg/kg), Tocilizumab, Nivolumab (.5 mg/kg)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Medical College of Wisconsin
Myelodysplastic Syndrome, Acute Leukemia
Reduced ATG Plus Mini PTCy for GVHD Prophylaxis in Haplo-SCT
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is regarded as a curative therapy for a variety of hematological malignancies and nonmalignant diseases.
- Trial name
- NCT06984536
- Testing
- Reduced ATG plus mini PTCy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking University People's Hospital
Leukemia, Lymphoma
Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic Cancer
RATIONALE: Nelfinavir mesylate and bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
- Conditions
- Leukemia, Lymphoma, Mature T-cell and Nk-cell Neoplasms, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT01164709
- Testing
- bortezomib, nelfinavir mesylate
- Where
- 4 sites in Switzerland
- Volunteers
- 18 people
- Sponsor
- Swiss Cancer Institute
Hematological Malignancies
Allogeneic Hematopoietic Stem Cell Transplantation With Reduced Intensity Pre-transplant Conditioning for the Treatment of High-risk Hematological Malignancies (V3)
This is study is for patients that have been diagnosed with high-risk hematological malignancies. The main purpose of this study is to confirm previously published results of stem cell transplantation with reduced intensity…
- Trial name
- NCT01139164
- Testing
- Regimen A, Regimen B, Regimen C
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Medical University of South Carolina
Myelodysplastic and Myeloproliferative Disorders, Acute Myelogenous Leukemia
Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)
Blood disorders such as leukemia or lymphoma or hemoglobinopathies can benefit from receiving an allogeneic (meaning that the cells are from a donor) stem cell transplant. Stem cells are created in the bone marrow.
- Conditions
- Myelodysplastic and Myeloproliferative Disorders, Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia
- Trial name
- NCT00579111
- Testing
- Campath, Busulfan, Fludarabine
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Baylor College of Medicine
Hematopoietic Stem Cell Transplantation, Hematologic Malignancy
The Association of Microbiota Composition With cGVHD After Allo-HSCT
Previous studies had found that the microbe in intestinal after allogeneic hematopoietic cell transplantation(allo-HSCT) were closely associated with overall survival and post-transplantation complications, especially graft…
- Conditions
- Hematopoietic Stem Cell Transplantation, Hematologic Malignancy, Chronic Graft-versus-host-disease, Complication
- Trial name
- NCT05355675
- Testing
- blood sample, stool sample
- Where
- 10 sites in China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Zhejiang University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.